Comparative Pharmacology
Head-to-head clinical analysis: ADVIL CONGESTION RELIEF versus ANAPROX DS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVIL CONGESTION RELIEF versus ANAPROX DS.
ADVIL CONGESTION RELIEF vs ANAPROX DS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ibuprofen: non-selective COX-1/COX-2 inhibitor reducing prostaglandin synthesis; phenylephrine: alpha-1 adrenergic receptor agonist causing vasoconstriction
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
1 tablet (ibuprofen 200 mg / phenylephrine 10 mg) orally every 4 hours while symptoms persist, not to exceed 6 tablets in 24 hours.
550 mg orally every 8 to 12 hours; maximum 1375 mg/day.
None Documented
None Documented
Ibuprofen: 2-4 hours (short half-life requires frequent dosing). Pseudoephedrine: 5-8 hours (longer in alkaline urine). Context: Half-life prolonged in renal impairment.
Terminal elimination half-life is approximately 12–17 hours (mean ~14 hours), allowing twice-daily dosing. Steady-state is achieved after 4–5 doses.
Renal: ~90% as unchanged drug and metabolites (ibuprofen: <10% unchanged, pseudoephedrine: 43-96% unchanged). Biliary/fecal: minimal (<5%).
Renal elimination of naproxen and its metabolites accounts for approximately 95% of the dose, with about 60% as unchanged drug and 40% as conjugated or hydroxylated metabolites. Biliary/fecal excretion is negligible (<5%).
Category C
Category C
NSAID/Decongestant Combination
NSAID